Contact Us

Diabetes is characterized by high presence of blood glucose, also called blood sugar, in the body. There are three main types of diabetes: type 1, type 2, and gestational diabetes. Oral glucose tolerance testing and hemoglobin A1c (HbA1c) testing are some of the tests used in the diagnosis of the chronic condition. Metformin, Sulfonylureas, Meglitinides, Thiazolidinediones, and Dipeptidyl peptidase-4 (DPP-4) inhibitors are some of the therapies used for the treatment of diabetes.

The global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market is estimated to account for US$ 118,955.0 Mn in terms of value in 2020 and is expected to reach US$ 231,909.8 Mn by the end of 2027.

Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market: Drivers

Increasing prevalence of diabetes is expected to propel growth of the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market over the forecast period. For instance, according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.

Moreover, high incidence of obesity is also expected to aid in growth of the market. For instance, according to the Centers of Disease Control and Prevention, Behavioral Risk Factor Surveillance System, 2018, 71424.3 thousand people in the U.S. suffer from obesity.     

Therapeutics held dominant position in the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market in 2019, accounting for 74.1% share in terms of value, followed by diagnosis & monitoring.

Figure 1. Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market Share (%) Value , by Category, 2019

Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics)  | Coherent Market Insights

Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market: Restraints

Lack of awareness about diabetes diagnostics and treatment, especially in emerging economies, is expected to hinder growth of the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market. The disease was considered common in older adults. However, the condition has spread among children and adolescents. According to the American Diabetes Association, in 2018, 7.3 million were undiagnosed with diabetes in the U.S.

Moreover, recall of diabetes drugs is also expected to limit growth of the market. For instance, in March 2020, JAMP Pharma Corporation voluntarily recalled Metformin, an anti-diabetic medication, from the Canadian market, owing to potential presence of nitrosamine impurities in the finished product.

Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market: Opportunities 

Increasing prevalence of diabetes in emerging economies is expected to offer lucrative growth opportunities for players in the market. For instance, according to the National Diabetes and Diabetic Retinopathy Survey report released Government of India, in October 2019, the prevalence of known diabetes cases was 8.0% and new diabetes cases was 3.8% in India during 2015-2019.

Moreover, R&D in diabetes is also expected to aid in growth of the market. For instance, in April 2020, researchers from University of Messina, Italy, reported that measurement of Band 3 protein anion exchange capability can aid in monitoring the impact of hyperglycemia on erythrocytes homeostasis.

The global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market was valued at US$ 108,190.4 Mn in 2019 and is forecast to reach a value of US$ 231,909.8 Mn by 2027 at a CAGR of 10.0% between 2020 and 2027.

Figure 2. Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics)  | Coherent Market Insights

Market Trends/Key Takeaways

In the U.S., the economic burden of diabetes is high. For instance, according to the study, ‘The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes, and Prediabetes’, published in the journal Diabetes Care, in April 2019, the economic burden associated with diagnosed diabetes, undiagnosed diabetes, prediabetes (adults), and gestational diabetes (mothers and newborns) reached US$ 327.2 billion, US$ 31.7 billion, US$ 43.4 billion for prediabetes, and US$ 1.6 billion for gestational diabetes, respectively, in 2017, in the U.S.

Development of novel approaches in administering insulin is expected to aid in growth of the market. For instance, in April 2020, researchers from Universidade de Lisboa, Portugal, reported that coating of insulin-loaded nanoparticles with chitosan can enhance peroral delivery of insulin.

Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market: Competitive Landscape

Major players operating in the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market include, Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, and Sanofi.

Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market: Key Developments

Major players in the market are focused on launching new products to expand their product portfolio. For instance, in April 2020, Companion Medical launched the new version of the InPen app, which offers a fixed dose and meal estimation dose calculator for people with Type 1 or Type 2 insulin-dependent diabetes.

Similarly, in March 2020, Nemaura Medical Inc. announced to launch proBEAT, a digital healthcare subscription service that aids in management of pre-diabetic and Type 2 diabetics, in the U.S.

Diabetes devices and drugs (diagnosis, monitoring and therapeutics) consists of diabetes management right from diagnosis, monitoring, till treatment. Diabetes is characterized by high presence of blood glucose, also called blood sugar, in the body. There are three main types of diabetes: type 1, type 2, and gestational diabetes. Oral glucose tolerance testing and hemoglobin A1c (HbA1c) testing are some of the tests used in the diagnosis of the chronic condition. Treatment options include use of insulin, oral hypoglycemic agents, and others.   

Restraints of the Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market

Lack of awareness about diabetes diagnostics and treatment, especially in emerging economies, is expected to hinder growth of the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market. Moreover, recall of diabetes drugs is also expected to limit growth of the market.

Key features of the study:

  • This report provides in-depth analysis of the global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, and Sanofi.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Category:
    • Diagnosis and Monitoring
      • Blood Glucose Monitoring Devices
      • Other Testing Devices
      • Software Programs for Diabetes Monitoring
      • Artificial Pancreas
    • Therapeutics
      • Insulin
      • Insulin Delivery
      • Oral Hypoglycemic Agents
      • Cell Therapies
  • Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Disease Type:
    • Type 2 Diabetes
    • Type 1 Diabetes
  • Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Geography:
    • North America
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country:
          • S.
          • Canada
    • Europe
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country:
          • K.
          • Germany
          • Italy
          • France
          • Spain
          • Russia
          • Rest of Europe
    • Asia Pacific
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country:
          • China
          • India
          • Japan
          • ASEAN
          • Australia
          • South Korea
          • Rest of Asia Pacific
    • Latin America
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country:
          • Brazil
          • Mexico
          • Argentina
          • Rest of Latin America
    • Middle East:
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country:
          • GCC
          • Israel
          • Rest of Middle East
    • Africa
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country/Region:
          • Central Africa
          • South Africa
          • North Africa
  • Company Profiles
    • Abbott Laboratories *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Bristol-Myers Squibb
    • DexCom, Inc.
    • Eli Lilly and Company
    • Companion Medical
    • GlaxoSmithKline plc
    • Glenmark Pharmaceuticals
    • Johnson & Johnson
    • Lupin Ltd.
    • Hoffmann-La Roche AG
    • Sanofi

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Category
      • Market Snippet, By Disease Type
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
  4. Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Category, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Diagnosis and Monitoring
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Blood Glucose Monitoring Devices
        • Other Testing Devices
        • Software Programs for Diabetes Monitoring
        • Artificial Pancreas
    • Therapeutics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Insulin
        • Insulin Delivery
        • Oral Hypoglycemic Agents
        • Cell Therapies
  5. Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Disease Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Type 2 Diabetes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Type 1 Diabetes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  6. Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • DexCom, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Companion Medical
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Glenmark Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Lupin Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 25 figures on “Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market – Global forecast to 2027.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users